{'fraction_non_alphanumeric': 0.02426837972876517, 'fraction_numerical': 0.011420413990007138, 'mean_word_length': 5.176211453744493, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Medium Chain Triglycerides Reduces Levels of Aβ-42 in Sprague Dawley with Cognitive Function Impairment

This study aims to find how Medium Chain Triglycerides (MCT) effect on biological markers of Alzheimer‘s disease, Amyloid-beta 42 (Aβ-42). The amyloid cascade hypothesis is the main hypothesis of the pathogenesis of Alzheimer's disease. This hypothesis explains that senile plaque which containing Amyloid-beta is neurotoxic and causing brain metabolism disorders. In Alzheimer’s disease, brain cells also lose their ability to use glucose as fuel, whereas glucose is the main energy source for brain metabolism. Medium Chain Triglycerides (MCT) consumption is expected to provide substitute energy for glucose after being metabolized by the liver to a ketone body, which is then released into the bloodstream to provide alternative energy sources as an energy source for the brain's metabolism to prevent the cognitive function from worsening. This study was an experimental study with post test only control group design and was performed on 24 induce rats (Sprague Dawley) divided into 4 groups, positive control, negative control, dose 1 MCT and dosed 2 MCT. Rats were treated with daily consumption of MCT during 4 weeks, then Aβ-42 levels were examined in rats CSF using ELISA method. The negative and positive control groups showed significantly higher Aβ-42 levels with groups taking MCT.